Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed ... diabetes, and kidney disease follows this proven playbook of tackling complex diseases with high unmet needs.

Jan 28 (Reuters) - The U.S. FDA has approved Novo Nordisk's (NOVOb.CO), opens new tab Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart ...

Inaxaplin targets APOL1-mediated kidney disease ... before its PDUFA date. Vertex could win approval for suzetrigine early, too. Keith Speights has positions in Vertex Pharmaceuticals.

Vertex has built an empire in cystic fibrosis ... The company's methodical expansion into pain, diabetes, and kidney disease follows this proven playbook of tackling complex diseases with high ...

Ratings for Vertex ... mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. Breaking Down Vertex Pharmaceuticals's ...

Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal ...